RxDoctor Payments Data

Greg Unfried, MD

Psychiatry · Evansville, INNPI 1194738211

Payments from drug & device makers

$484in general payments, 2019–2025

Across 16 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$144
  • Neurocrine Biosciences, Inc.$129
  • Otsuka America Pharmaceutical, Inc.$67
  • Johnson & Johnson$45
  • Vanda Pharmaceuticals Inc.$40
  • Indivior Inc.$31
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$484 in reported general payments places this provider in the 55th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$22,804
Medicare patients
72
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate85$258,546
Invega TrinzaPaliperidone Palmitate13$124,644
IngrezzaValbenazine Tosylate12$99,846
RexultiBrexpiprazole28$38,953
Abilify MaintenaAripiprazole13$37,949
Risperdal ConstaRisperidone Microspheres26$24,453
Olanzapine206$22,258
AristadaAripiprazole Lauroxil12$21,545
FanaptIloperidone11$19,072
Clozapine221$17,235
SecuadoAsenapine12$16,872
Olanzapine OdtOlanzapine57$12,429
Lurasidone Hcl51$10,082
Divalproex Sodium ErDivalproex Sodium89$6,809
Paliperidone ErPaliperidone17$5,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$45$407,643124 claims
Neurocrine Biosciences, Inc.Ingrezza$129$99,84612 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$67$76,90241 claims
Alkermes, Inc.Aristada$12$21,54512 claims
Vanda Pharmaceuticals Inc.Fanapt$40$19,07211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →